Clinical Trial Detail

NCT ID NCT02370238
Title A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Recruitment Unknown status
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dompé Farmaceutici S.p.A
Indications

triple-receptor negative breast cancer

Therapies

Reparixin

Age Groups: adult

No variant requirements are available.